M N Sabbagh

Summary

Affiliation: Sun Health Research Institute
Country: USA

Publications

  1. ncbi request reprint Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
    Sandip Ray
    Satoris, Inc, 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA
    Nat Med 13:1359-62. 2007
  2. ncbi request reprint Smoking affects the phenotype of Alzheimer disease
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Neurology 64:1301-3. 2005
  3. ncbi request reprint The use of memantine in dementia with Lewy bodies
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 7:285-9. 2005
  4. ncbi request reprint Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer's disease
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research Sun Health Research Institute, Sun City, AZ 85351, USA
    Curr Alzheimer Res 3:157-60. 2006
  5. ncbi request reprint Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging
    Marwan N Sabbagh
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Arch Neurol 63:1771-6. 2006
  6. ncbi request reprint Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease?
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Parkinsonism Relat Disord 11:311-5. 2005
  7. ncbi request reprint Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Dement Geriatr Cogn Disord 24:327-34. 2007
  8. ncbi request reprint Is there a characteristic lipid profile in Alzheimer's disease?
    Marwan Sabbagh
    The Cleo Roberts Center for Clinical Research, USA
    J Alzheimers Dis 6:585-9; discussion 673-81. 2004
  9. ncbi request reprint Case series of clinically probable dementia with Lewy bodies in two Native Americans
    Marwan N Sabbagh
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Alzheimer Dis Assoc Disord 18:259-60. 2004
  10. pmc Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics"
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ, USA
    Alzheimers Dement 4:174-5. 2008

Research Grants

Collaborators

Detail Information

Publications58

  1. ncbi request reprint Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
    Sandip Ray
    Satoris, Inc, 2686 Middlefield Road, Suite E, Redwood City, California 94063, USA
    Nat Med 13:1359-62. 2007
    ..Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease...
  2. ncbi request reprint Smoking affects the phenotype of Alzheimer disease
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Neurology 64:1301-3. 2005
    ..Smoking status was not associated with cognitive or neuropathologic measures. However, active smokers were significantly younger at death and higher levels of smoking were associated with shorter disease duration...
  3. ncbi request reprint The use of memantine in dementia with Lewy bodies
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 7:285-9. 2005
    ..To determine the effect of memantine in the treatment of Dementia with Lewy Bodies (DLB)...
  4. ncbi request reprint Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer's disease
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research Sun Health Research Institute, Sun City, AZ 85351, USA
    Curr Alzheimer Res 3:157-60. 2006
    ..To determine whether Apolipoprotein E4 (Apo E4) gene status or ApoE gene dose affect the lipid profile in AD...
  5. ncbi request reprint Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging
    Marwan N Sabbagh
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Arch Neurol 63:1771-6. 2006
    ..Decreased neocortical nicotinic receptor binding is characteristic of AD but has not been investigated in subjects with MCI...
  6. ncbi request reprint Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease?
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Parkinsonism Relat Disord 11:311-5. 2005
    ..647, P<0.001, respectively). The UPDRS correlated with the GDS and FAST more closely in PD than in AD. Similar to AD, functional declines in PD correlates with cognitive decline and may be influenced by motor disability in PD...
  7. ncbi request reprint Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Dement Geriatr Cogn Disord 24:327-34. 2007
    ..We now determine if the correlation between cognitive impairment and functional ability in PD is similar to that in AD using individual cognitive measures...
  8. ncbi request reprint Is there a characteristic lipid profile in Alzheimer's disease?
    Marwan Sabbagh
    The Cleo Roberts Center for Clinical Research, USA
    J Alzheimers Dis 6:585-9; discussion 673-81. 2004
    ..To characterize the lipid profile in Alzheimer's Disease (AD) and to determine whether it differs from the cardiac risk profile...
  9. ncbi request reprint Case series of clinically probable dementia with Lewy bodies in two Native Americans
    Marwan N Sabbagh
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Alzheimer Dis Assoc Disord 18:259-60. 2004
    ..Here, we report 2 cases of clinically probable dementia with Lewy bodies (DLB) that fulfill McKeith Consensus Criteria in an 84-year-old full-blooded Navajo woman and a 78-year-old full-blooded Navajo male assessed in a neurology clinic...
  10. pmc Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics"
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ, USA
    Alzheimers Dement 4:174-5. 2008
  11. pmc Parkinson disease with dementia: comparing patients with and without Alzheimer pathology
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Harold Civin Laboratory of Neuropathology, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Alzheimer Dis Assoc Disord 23:295-7. 2009
    ..PDD-AD and PDD+AD have similar degrees of dementia and approximately half of PDD subjects have enough AD pathology to attain a neuropathologic diagnosis of AD. PDD can develop in the absence of significant Alzheimer pathology...
  12. ncbi request reprint Length of stay in skilled nursing facilities is longer for patients with dementia
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 5:57-63. 2003
    ..It is likely that demented patients enter for non-physical, cognitive related reasons. These results may help families and institutions plan for long-term care...
  13. pmc Correlation of clinical features with argyrophilic grains at autopsy
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Alzheimer Dis Assoc Disord 23:229-33. 2009
    ..AGs can occur with or without neurodegenerative conditions and can occur in the absence of significant cognitive decline. AGs are not clearly associated with any single comorbid health condition...
  14. ncbi request reprint The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 4:317-25. 2002
    ..Thus, while controversies still exist, ongoing research is illuminating how nicotinic receptor changes and functions may be relevant to clinical, pathological and neurochemical changes that occur in AD...
  15. ncbi request reprint Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies
    M N Sabbagh
    Department of Neurosciences, UCSD, La Jolla, CA, USA
    J Neural Transm 108:1149-57. 2001
    ..Loss of nAChR activity does not appear to be related to plaques or NFTs in AD or DLB...
  16. pmc Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD
    M N Sabbagh
    The Cleo Roberts Center, Banner Sun Health Research Institute, 10515 W Santa Fe Dr Sun City, AZ 85351, USA
    Curr Alzheimer Res 7:280-6. 2010
    ..Cognitive, global and functional instruments have been extensively investigated for correlations with neuropathological changes such as neurofibrillary tangles (NFTs), plaques, and synapse loss in the brain...
  17. ncbi request reprint E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease
    J Corey-Bloom
    Department of Neurosciences, University of California, San Diego, La Jolla, USA
    Neurology 54:403-6. 2000
    ..To investigate the relationship between apolipoprotein E (APOE) genotype and both cholinergic dysfunction and synapse loss in AD...
  18. ncbi request reprint Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease
    R T Reid
    Erik and Ese Banck Clinical Research Center, San Diego, CA, USA
    J Neural Transm 108:1043-50. 2001
    ..4, and 6.0 +/- 1.0 fmol/mg protein for epsilon-/epsilon-, epsilon4/epsilon-, and epsilon4/epsilon4 respectively. We conclude that the presence or absence of the Apo-E4 genotype does not influence the loss of high affinity nAChR in AD...
  19. ncbi request reprint Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease
    J N Caviness
    Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, USA
    Parkinsonism Relat Disord 13:348-54. 2007
    ..PD-MCI has mean quantitative EEG characteristics that represent an intermediate electrophysiological state between PD-CogNL and PD-D...
  20. ncbi request reprint Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial
    D L Sparks
    Sun Health Research Institute, Sun City, AZ 85351, USA
    Acta Neurol Scand Suppl 185:3-7. 2006
    ..Recent evidence suggests that treatment of mild-to-moderate Alzheimer's disease (AD) with atorvastatin provides significant benefit on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-cog) after 6 months...
  21. pmc Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction
    Thomas G Beach
    Sun Health Research Institute, Sun City, AZ 85351, USA
    Acta Neuropathol 117:613-34. 2009
    ..It is suggested that the proposed staging system would improve on its predecessors by allowing classification of a much greater proportion of cases...
  22. pmc Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort
    D Larry Sparks
    Roberts Laboratory for Neurodegenerative Disease Research, Sun Health Research Institute, Sun City, Ariz, USA
    Neurodegener Dis 7:183-6. 2010
    ....
  23. ncbi request reprint Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro
    Richard T Reid
    Erik and Ese Banck Clinical Research Center, San Diego, CA, USA
    J Alzheimers Dis 5:429-36. 2003
    ..Furthermore, the lack of an effect on the alpha 7-nAChRs in PC-12 cells suggests that the increase in cortical alpha 7 nAChRs may be an indirect effect of increased acetylcholine levels in vivo...
  24. doi request reprint Pathologic findings in prospectively ascertained essential tremor subjects
    H A Shill
    Sun Health Research Institute, Sun City, AZ, USA
    Neurology 70:1452-5. 2008
    ..To assess pathologic changes in prospectively characterized subjects with essential tremor (ET)...
  25. pmc Possible Alzheimer's disease in an apolipoprotein E2 homozygote
    Ignat Ignatov
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ, USA
    J Alzheimers Dis 16:35-8. 2009
    ..5 years. The patient is currently treated with donepezil and memantine. In conclusion, a clinically confirmed case of Alzheimer's disease is rare in Apo E2 homozygotes but can occur...
  26. ncbi request reprint Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits
    Thomas G Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 114:419-24. 2007
    ....
  27. pmc The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007
    Thomas G Beach
    Sun Health Research Institute, Sun City, 85351, USA
    Cell Tissue Bank 9:229-45. 2008
    ....
  28. pmc Reduced striatal tyrosine hydroxylase in incidental Lewy body disease
    Thomas Gerald Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 115:445-51. 2008
    ..8% (P = 0.01) reduction in ILBD cases, as compared with control cases. The finding suggests that ILBD is not a benign condition but is likely a precursor to PD and/or DLB...
  29. ncbi request reprint Reduced risk of incident AD with elective statin use in a clinical trial cohort
    D Larry Sparks
    Roberts Laboratory for Neurodegenerative Disease Research, Sun Health Research Institute, Sun City AZ, USA
    Curr Alzheimer Res 5:416-21. 2008
    ..Cholesterol levels were lower among statin users compared with non-LLA users, but the MMSE scores were equivalent. The data suggest that statin therapy may be of benefit in reducing the risk of AD...
  30. ncbi request reprint Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results
    D Larry Sparks
    Author Affiliations Sun Health Research Institute, Sun City, AZ 85351, USA
    Arch Neurol 62:753-7. 2005
    ....
  31. ncbi request reprint Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD
    D Larry Sparks
    SunHealth Research Institute, USA
    Curr Alzheimer Res 2:343-53. 2005
    ..Accordingly, atorvastatin therapy may be an effective treatment and may slow the progression of AD among mild-to-moderately affected patients...
  32. ncbi request reprint Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?
    D Larry Sparks
    Laboratory of Neurodegenerative Disease Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Mol Neurosci 19:209-12. 2002
    ..Based on this observation we suggest that cholesterol levels should be actively monitored in the elderly, as many individuals with AD are over 65 years of age and therefore excluded by currently accepted guidelines...
  33. ncbi request reprint Is cholesterol a culprit in Alzheimer's disease?
    D Larry Sparks
    Laboratory for Neurodegenerative Disease Research, Sun Health Research Institute, Sun City, Arizona 85351, USA
    Int Psychogeriatr 15:153-9. 2003
    ..Nevertheless, the foregoing suggests that routine monitoring and intervention for elevated cholesterol levels among the elderly could promote more than a healthy heart...
  34. ncbi request reprint Donepezil: potential neuroprotective and disease-modifying effects
    Sandra A Jacobson
    Research Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351, USA
    Expert Opin Drug Metab Toxicol 4:1363-9. 2008
    ..The evidence seems to be strongest in relation to donepezil, which is the focus of this review...
  35. ncbi request reprint Interaction of cardiovascular disease and neurodegeneration: transcranial Doppler ultrasonography and Alzheimer's disease
    Alex E Roher
    Longtine Center for Molecular Biology and Genetics, Sun Health Research Institute, Sun City AZ 85351, USA
    Neurol Res 28:672-8. 2006
    ..In this study, we examine the arteries of the circle of Willis by transcranial Doppler (TCD) ultrasonography...
  36. doi request reprint Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy
    Marwan N Sabbagh
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ, USA Marwan
    Alzheimers Dement 4:S109-18. 2008
    ..In this perspective, we review trial design and discuss the use of biomarkers by using lessons learned from previous trials conducted with cholinergic therapy...
  37. ncbi request reprint Pathological correlates of cognitive decline in Alzheimer's disease
    K Thind
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Panminerva Med 49:191-5. 2007
    ..In general, tangles and synaptic loss are better correlates of cognitive decline and correlate better...
  38. pmc Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials
    Donald J Connor
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ, USA
    Alzheimers Dement 4:390-4. 2008
    ..The Neuropsychiatric Inventory (NPI) is commonly used in dementia trials to quantify and qualitate changes in psychiatric symptoms...
  39. pmc Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders
    Thomas G Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 117:169-74. 2009
    ..It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy...
  40. pmc Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
    Alex E Roher
    The Longtine Center for Molecular Biology and Genetics, Sun Health Research Institute, Sun City, AZ, USA
    Alzheimers Dement 5:18-29. 2009
    ..We evaluated the amounts of amyloid beta (Abeta)) peptides in the central nervous system (CNS) and in reservoirs outside the CNS and their potential impact on Abeta plasma levels and Alzheimer's disease (AD) pathology...
  41. pmc Administration and scoring variance on the ADAS-Cog
    Donald J Connor
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 15:461-4. 2008
    ....
  42. ncbi request reprint HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier
    D L Sparks
    D Larry Sparks, Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351, USA E mail
    J Nutr Health Aging 6:324-31. 2002
    ....
  43. doi request reprint Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind)
    Marwan N Sabbagh
    Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Neurosci Lett 448:217-20. 2008
    ....
  44. pmc Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders
    Thomas G Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 119:689-702. 2010
    ..Within the gastrointestinal tract, there was a rostrocaudal gradient of decreasing PASH frequency and density, with the lower esophagus and submandibular gland having the greatest involvement and the colon and rectum the lowest...
  45. pmc Challenges to the recognition and assessment of Alzheimer's disease in American Indians of the southwestern United States
    Trudy Griffin-Pierce
    Department of Anthropology, University of Arizona, Tucson, AZ, USA
    Alzheimers Dement 4:291-9. 2008
    ....
  46. pmc Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea
    Marwan N Sabbagh
    Banner Sun Health Research Institute, The Cleo Roberts Center for Clinical Research, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Curr Opin Investig Drugs 11:80-91. 2010
    ..Given the robustness of the phase II clinical data, latrepirdine has a high likelihood of success in phase III trials and in subsequently being granted regulatory approval...
  47. pmc Are certain lifestyle habits associated with lower Alzheimer's disease risk?
    Lana Arab
    The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, Sun City, AZ 85351, USA
    J Alzheimers Dis 20:785-94. 2010
    ..In this review, lifestyle habits are reviewed as they pertain to influence on risk of developing AD as well as on cognitive decline. Epidemiological studies and animal studies are reviewed...
  48. pmc Drug development for Alzheimer's disease: where are we now and where are we headed?
    Marwan N Sabbagh
    The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, Sun City, AZ 85351, USA
    Am J Geriatr Pharmacother 7:167-85. 2009
    ..The aim of this article was to provide a survey of the clinical development of pharmacotherapy for Alzheimer's disease (AD)...
  49. ncbi request reprint Defining mild cognitive impairment in Parkinson's disease
    John N Caviness
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Mov Disord 22:1272-7. 2007
    ..Defining PD-MCI offers an opportunity for further study of cognitive impairment in PD and targets for earlier therapeutic intervention...
  50. ncbi request reprint Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment
    Sterling C Johnson
    Geriatric Research Education and Clinical Center, Wm S Middleton VA Hospital, Madison, WI 53705, USA
    Neuropsychologia 42:980-9. 2004
    ..Results suggest that the medial temporal response over repeated presentation is related to clinical status. Probes of incremental encoding processes over trials may be useful markers of medial temporal lobe integrity...
  51. ncbi request reprint Sensitivity to expectancy violations in healthy aging and mild cognitive impairment
    Juliet E Davie
    Department of Speech and Hearing Science, Arizona State University, Tempe, AZ 85287 0102, USA
    Neuropsychology 18:269-75. 2004
    ..The findings suggest that individuals with MCI are inordinately sensitive to expectancy violations, and these findings are discussed in terms of possible executive dysfunction...
  52. ncbi request reprint Relationship of cognitive measures and gray and white matter in Alzheimer's disease
    Leslie C Baxter
    Barrow Neurological Institute, Phoenix, AZ 85013, USA
    J Alzheimers Dis 9:253-60. 2006
    ..To examine the relationship between commonly used screening cognitive measures with gray and white matter integrity in patients with mild to moderate AD...
  53. doi request reprint Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk
    Joseph Rogers
    Neurology 70:5-6. 2008
  54. ncbi request reprint Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease
    John N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Mov Disord 18:1157-62. 2003
    ..These results have mechanistic implications for cortical dysfunction in Parkinson's disease and for cortical myoclonus in general...
  55. ncbi request reprint Detecting Alzheimer disease before it happens: The key to prevention?
    Joseph Quinn
    Neurology 71:78-9. 2008
  56. ncbi request reprint Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease
    John N Caviness
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mov Disord 21:492-9. 2006
    ..The small amplitude postural tremor in PD arises from heterogeneous oscillator mechanisms. The discovery of increased corticomuscular coupling shows cortical involvement in the small amplitude postural tremor of PD...
  57. pmc Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment
    Jon Valla
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Arizona Alzheimer s Disease Consortium, 350 W Thomas Road, Phoenix, AZ 85013, USA
    Mitochondrion 6:323-30. 2006
    ..This report confirms mitochondrial deficiencies in AD, extends them to MCI, and suggests they are present at the earliest symptomatic stages of disease...
  58. ncbi request reprint Progressive aphasia with Lewy bodies
    Richard J Caselli
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, AZ 85259, USA
    Dement Geriatr Cogn Disord 14:55-8. 2002
    ....

Research Grants1

  1. Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease
    Marwan N Sabbagh; Fiscal Year: 2010
    ..We propose that Thalidomide may represent a BACE1 inhibitor. ..